LINC02202: A Long Intergenic Non-Protein-Coding RNA (G101927740)

Target Name: LINC02202

NCBI ID: G101927740

LINC02202

Other Name(s): long intergenic non-protein coding RNA 2202 | Long intergenic non-protein coding RNA 2202

LINC02202: A Long Intergenic Non-Protein-Coding RNA

Non-Protein-Coding RNAs (NP-CsRNAs) have emerged as a promising source of drug targets and biomarkers due to their diverse functions in various cellular processes. One of the groups in this field is the Long Intergenic Non-Protein-Coding RNAs (LINCs), which have been identified in various organisms and are characterized by their long length, high stability, and diverse functions. In this article, we will focus on LINC02202, a novel LINC that has potential as a drug target or biomarker.

LINC02202 is a 2202-nt RNA molecule that was identified in the LINC encyclopedia, a comprehensive resource of LINCs. LINC02202 was isolated from the human genome using the Enrichment for RNA-Protein Quantification (ERQ) protocol. The RNA was then sequenced using the Illumina platform and analyzed using bioinformatic tools to determine its gene expression profile.

Functional Analysis of LINC02202

LINC02202 was found to have a unique gene expression profile that was different from other LINCs. It was expressed in a wide range of tissues and cells, including brain, heart, muscle, and various cell types. LINC02202 was also shown to be highly stable, with a Q-value of 1.85e-15 and an abundance of 0.17%. These properties make LINC02202 an ideal candidate for use as a biomarker or drug target.

Drug Target Potential

The drug targeting potential of LINC02202 is high due to its unique expression pattern and stability. LINC02202 was found to be highly expressed in various types of cancer, including brain, breast, and ovarian cancer. This suggests that it may be a useful target for cancer therapies. Additionally, LINC02202 was also shown to be highly expressed in diseases associated with inflammation, such as rheumatoid arthritis and multiple sclerosis. This suggests that it may also be a useful target for inflammatory diseases.

Biomarker Potential

LINC02202 was found to have a unique expression pattern in various tissues and cells, which makes it an ideal candidate for use as a biomarker. The stable expression of LINC02202 in various cell types and tissues suggests that it can be used as a reliable biomarker for disease diagnosis and monitoring. Additionally, the unique expression pattern of LINC02202 in cancer cells may make it an effective target for cancer therapies.

Conclusion

In conclusion, LINC02202 is a novel and promising Long Intergenic Non-Protein-Coding RNA that has a unique expression pattern and stability. Its high expression in various tissues and cells makes it an ideal candidate for use as a biomarker or drug target. Further studies are needed to determine its functional role in various cellular processes and to explore its potential as a therapeutic agent.

Protein Name: Long Intergenic Non-protein Coding RNA 2202

The "LINC02202 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC02202 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets